The protective effects of dexmedetomidine on perioperative myocardial injury in patients with hypertensive myocardial hypertrophy

doi:10.13459/j.cnki.cjap.2016.05.019

Abstract

Abstract: Objective: The purpose of this study was to evaluate the effects of dexmedetomidine (DEX) on patients with hypertensive myocardial hypertrophy.Methods: Fifty four patients with hypertensive myocardial hypertrophy were enrolled in the study and were randomly divided into two groups (n=27). Patients in groupD were pretreated with DEX (1 μg/kg) before induction and then maintain with 0.5 μg/(kg·h) DEX. Patients in group C were pretreated with saline at the same time. All patients were connected with holter recorder 2 h before anesthesia and were continuously recorded for 24 h. Blood sample were collected to measure ischemia modified albumin(IMA) and serum cardiac troponin I (cTnI) at the time of T0 (before induction), T1(1 h after surgery), T2(4 h after surgery), T3(12 h after surgery) and T4(24 h after surgery). The surgery time, blood loss and side effect of two groups were recorded at the same time.Results: The serum IMA level in group D was lower than that of group C at the time of T1, T2 and T3 (P<0.05). The serum cTnI in group C was higher than that of group D at the time of T1, T2, T3 and T4 (P<0.05). Changes of ST and complicated ventricular arrhythmias ingroup D were lower than those of group C (P<0.05).Conclusion: DEX could reduce the incidence of myocardial damage, changes of ST and complicated ventricular arrhythmias in patients with hypertensive myocardial hypertrophy.

Key words: dexmedetomidine, hypertension, myocardial hypertrophy, myocardial protection

WU Yong, ZHANG Xiao-bao, QIAN Yan-ning, XIAO Hang. The protective effects of dexmedetomidine on perioperative myocardial injury in patients with hypertensive myocardial hypertrophy[J]. CJAP, 2016, 32(5): 459-462.

References

[1] Teniente VR, Solorio S, Vargas SE, et al.Improvement of diastolic function after regression of left ventricular hypertrophy[J]. Arch Cardiol Mex, 2008, 78(4):392-399.
[2] Okin PM, Kjeldsen SE, Julius S, et al.All-cause and cardiovascular mortalityin relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy[J]. Eur Heart J, 2010, 31(18):2271-2279.
[3] Ueshima K, Yasuno S, Oba K, et al.Effects of cardiac complicationson cardiovascular events in Japanese high-risk hypertensive patients:subanalysis of the CASE-J trial[J]. Cire J, 2009, 73(6):1080-1085.
[4] Verdecchia P, Angeli F, Achilli P, et al.Echocardiographic left ventricularhypertrophy in hypertension:marker for future events or mediator of events[J]. Curr Opin Cardiol, 2007, 22(4):329-334.
[5] Cohn JN, Yellin AM. Learned precise cardiovascular control through graded central sympathetic stimulation[J]. J Hypertens Suppl, 1984, 2(3):77-79.
[6] Jobe LJ, Melendez GC, Levick SP, et al.TNF-alpha inhibition attenuates adverse myocardial remodeling in a rat model of volume overload[J]. Am J PhysiolHeart Circ Physiol, 2009, 297(4):1462-1468.
[7] Taniguehi T, Kurita A, Kobayashi K, et al.Dose and time related effects of dexmedetomidine on mortality and inflammatory responses to endotoxin-induced shock in rats[J]. J Anesth, 2008, 22(3):221-228.
[8] Lang RM, Bierig M, Devereux RB, et al.Recommendations for chamber quantification:a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology[J]. J Am Soc Echocardiogr, 2005, 18(12):1440-1463.
[9] Diez J. Towards a new paradigm about hypertensive heart disease[J]. Med Clin North Am, 2009, 93(3):637-645.
[10] 周荣, 田橙, 郑智. 原发性高血压左心室不同构型心律失常的比较[J]. 中华心律失常杂志, 2002, 6(2):75.
[11] 王变珍, 郭果林. 高血压病发生心律失常的临床观察及研究[J]. 实用心电学杂志, 2007, 16(2):108.
[12] Drazner MH. The progression of hypertensive heart disease[J].Circulation, 2011, 123(3):327-334.
[13] 杨静, 李立环. 围术期心肌缺血的监测和治疗[J]. 临床麻醉学杂志,2006, 22(9):719-721.
[14] Tobias JD, Chrysostomou C. Dexmedetomidine:antiarrhythmic effects in the pediatric cardiac patient[J]. Pediatr Cardiol, 2013, 34(4):779-785.
[15] Ji F, Li Z, Nguyen H, et al.Perioperative Dexmedetomidine Improves Outcomes of Cardiac Surgery[J]. Circulation, 2013, 127(15):1576-1584.
[16] Roekaerts PM, Prinzen FW, De Lange S. Beneficial effects of dexmedetomidineon ischaemic myocardium of anaesthetized dogs[J]. Br J Anaesth, 1996, 77(3):427-429.
[17] Ibacache M, Sanchez G, Pedrozo Z, et al.Dexmedetomidine preconditioning activates pro-survival kinases and attenuates regional ischemia/reperfusion injury in rat heart[J]. Biochimica Biophysica Acta, 2012, 1822(4):537-545.